Pharmacopeia

CWP-0084

DOBUTAMINE

Cardiovascular · Level 2

Core pharmacology

Class Group

ADRENERGIC

Introduction

synthetic catechol derivative of isoprenaline

Indications Uses

1. Inotropic support in low cardiac output secondary to MI, cardiac surgery, cardiomyopathy
2. Cardiac stress testing

Presentation

Is a racemic mixture. White
powder for reconstitution(250mg) or Clear fluid 12.5mg/ml in 20ml vials.
Should not be
mixed with alkaline solutions (HCO3)

Main Action

the + enantiomer is a potent α1 antagonist
and β1 agonist, the -ve enantiomer has
opposite effects on α1 causing agonism and
is less potent (10%) β1 agonist.

Mechanism of action

Predominant mechanism is via direct acting B1 stimulation (increased cAMP) and retains a small amount of B2 effects

Physiological effects

composite of α and β actions.
Mostly β1 effect: ↑ ino+ chrono tropy and MVO2.
Mild β2 eff¬ects.

Detail:

CVS
- Beta1 effects lead to increased SA node activation (increased chronotropy), increased dromotropy and increased inotropy, thereby increasing cardiac output (inotropy greatest)
- Coronary artery vasodilator
- Beta-2 activity tends to decrease LVEDP and SVR, contributing to increased CO and cardiac index
- Increased MVO2
- Increased risk of arrhythmias (especially at doses >10mcg/kg/min)
- Should be avoided in patients with cardiac outflow obstruction (AS, tamponade)

Resp
- Modest pulmonary vasodilation
- Inhibits HPV

Renal- Increased RBF due to increased CO may occur

Adverse Effects Toxicity

1. Arrhythmias (especially at doses >10mcg/kg/min)
2. Arrest in fixed output patients (AS, tamponade)
3. Increased MVO2
4. Eosinophilic myocarditis in prolonged infusion

Absorption

IV, dose starts at 5mcg/kg/min uptitrate to
e¬ffect, max 40mcg/kg/min

Distribution

Small vd

Volume of distribution

0.2L/kg

Metabolism

via COMT then gluruonidation hepatically

Excretion

urine as inactive metabolites

Half-life

2 minutes

Route And Dose

IV Infusion
Dose range 0.5-40mcg/kg/min. Response within 2 minutes